Marianne Martinello

Senior Lecturer

Marianne is an Infectious Diseases Physician and Postdoctoral Research Fellow in the Viral Hepatitis Clinical Research Program and Blacktown Mt Druitt Hospital, Sydney. Her research interests include therapeutic strategies for acute and chronic HCV infection, including co-infection with HIV.

publications

Journal articles
add
Dore GJ; Feld JJ; Thompson A; Martinello M; Muir AJ; Agarwal K; Müllhaupt B; Wedemeyer H; Lacombe K; Matthews GV; Schultz M; Klein M; Hezode C; Mercade GE; Kho D; Petoumenos K; Marks P; Tatsch F; Dos Santos AGP; Gane E, 2020, 'Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial', Journal of Hepatology, vol. 72, pp. 431 - 440, http://dx.doi.org/10.1016/j.jhep.2019.10.010
2020
Schierhout G; McGregor S; Gessain A; Einsiedel L; Martinello M; Kaldor J, 2020, 'Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies', The Lancet Infectious Diseases, vol. 20, pp. 133 - 143, http://dx.doi.org/10.1016/S1473-3099(19)30402-5
2020
Dore GJ; Martinello M; Alavi M; Grebely J, 2020, 'Global elimination of hepatitis C virus by 2030: why not?', Nature Medicine, vol. 26, pp. 157 - 160, http://dx.doi.org/10.1038/s41591-019-0706-x
2020
Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ; Peolim L; How-Chow D; Telenta J; Harvey P; Jones S; Dunlop A; Treloar C; Samuel Y; Poeder F; Crawford S; Baxter A; Keats J; Mowat Y; Silk D; Micallef M; Tamaddoni M; Marks P; Lamoury F; Jayasinghe I; Reid H; Cunningham EB; Bartlett S; Jacka B; Erratt A; Jauncey M; Collie P; Lam T; Gilliver R; Hazelwood S; Houlihan N; Burns C; Lewis R; Morris D; Donohue K; Carthew A; Horasak N; Cherry R; Shin S; Peterson D; Sellwood T; McKeown W; Pritchard-Jones J; Smyth F; Adey S; Clark K, 2020, 'Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study', Journal of Viral Hepatitis, vol. 27, pp. 281 - 293, http://dx.doi.org/10.1111/jvh.13233
2020
Bradshaw D; Vasylyeva TI; Davis C; Pybus OG; Thézé J; Thomson EC; Martinello M; Matthews GV; Burholt R; Gilleece Y; Cooke GS; Page EE; Waters L; Nelson M, 2020, 'Transmission of hepatitis C virus in HIV-positive and PrEP-using MSM in England', Journal of Viral Hepatitis, http://dx.doi.org/10.1111/jvh.13286
2020
Grebely J; Read P; Cunningham EB; Weltman M; Matthews GV; Dunlop A; Montebello M; Martinello M; Gilliver R; Marks P; Applegate TL; Dore GJ, 2020, 'Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO‐C): An open‐label, single‐arm, phase 4, multicentre trial', Health Science Reports, http://dx.doi.org/10.1002/hsr2.151
2020
Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Janjua NZ; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J, 2020, 'Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis', Journal of Hepatology, vol. 72, pp. 643 - 657, http://dx.doi.org/10.1016/j.jhep.2019.11.012
2020
Martinello M; Orkin C; Cooke G; Bhagani S; Gane E; Kulasegaram R; Shaw D; Tu E; Petoumenos K; Marks P; Grebely J; Dore GJ; Nelson M; Matthews GV, 2019, 'Short duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with recent HCV infection.', Hepatology, http://dx.doi.org/10.1002/hep.31003
2019
Martinello M; Matthews GV, 2019, 'Management of acute HCV in the era of direct-acting antivirals: implications for elimination', The Lancet Gastroenterology and Hepatology, vol. 4, pp. 256 - 257, http://dx.doi.org/10.1016/S2468-1253(19)30001-9
2019
Martinello M; Yee J; Bartlett SR; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle J; Shaw D; Hellard M; Petoumenos K; Lin L; Marks P; Applegate T; Dore GJ; Matthews GV; CEASE study team , 2019, 'Moving towards hepatitis C micro-elimination among people living with HIV in Australia: the CEASE study.', Clin Infect Dis, http://dx.doi.org/10.1093/cid/ciz985
2019
Bajis S; Grebely J; Cooper L; Smith J; Owen G; Chudleigh A; Hajarizadeh B; Martinello M; Adey S; Read P; Gilliver R; Applegate T; Treloar C; Maher L; Dore GJ, 2019, 'Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study', Journal of Viral Hepatitis, vol. 26, pp. 969 - 979, http://dx.doi.org/10.1111/jvh.13112
2019
Bartlett SR; Applegate TL; Jacka BP; Martinello M; Lamoury FMJ; Danta M; Bradshaw D; Shaw D; Lloyd AR; Hellard M; Dore GJ; Matthews GV; Grebely J, 2019, 'A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015', Journal of the International AIDS Society, vol. 22, pp. e25222, http://dx.doi.org/10.1002/jia2.25222
2019
Olmstead AD; Montoya V; Chui CK; Dong W; Joy JB; Tai V; Poon AFY; Nguyen T; Brumme CJ; Martinello M; Matthews GV; Richard Harrigan P; Dore GJ; Applegate TL; Grebely J; Howe AYM, 2019, 'A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections', Infection, Genetics and Evolution, vol. 69, pp. 76 - 84, http://dx.doi.org/10.1016/j.meegid.2019.01.016
2019
Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2018, 'Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia', Journal of Viral Hepatitis, vol. 25, pp. 640 - 648, http://dx.doi.org/10.1111/jvh.12852
2018
Martinello M; Dore GJ; Skurowski J; Bopage RI; Finlayson R; Baker D; Bloch M; Matthews GV, 2018, 'Erratum: Antiretroviral use in the CEASE cohort study and implications for direct-acting antiviral therapy in human immunodeficiency virus/hepatitis C virus coinfection (Open Forum Infect Diss (2016)3:2(ofw105) DOI: 10.1093/ofid/ofw105)', Open Forum Infectious Diseases, vol. 5, http://dx.doi.org/10.1093/ofid/ofy033
2018
Lamoury FMJ; Bajis S; Hajarizadeh B; Marshall AD; Martinello M; Ivanova E; Catlett B; Mowat Y; Marks P; Amin J; Smith J; Ezard N; Cock V; Hayllar J; Persing DH; Kleman M; Cunningham P; Dore GJ; Applegate TL; Grebely J, 2018, 'Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay', Journal of Infectious Diseases, vol. 217, pp. 1889 - 1896, http://dx.doi.org/10.1093/infdis/jiy114
2018
Martinello M; Dore GJ; Matthews GV; Grebely J, 2018, 'Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs', Infectious Disease Clinics of North America, vol. 32, pp. 371 - 393, http://dx.doi.org/10.1016/j.idc.2018.02.003
2018
Martinello M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Grebely J; Nelson M; Matthews GV, 2018, 'Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection', Journal of Viral Hepatitis, vol. 25, pp. 1180 - 1188, http://dx.doi.org/10.1111/jvh.12917
2018
Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV, 2018, 'Management of acute HCV infection in the era of direct-acting antiviral therapy', Nature Reviews Gastroenterology and Hepatology, vol. 15, pp. 412 - 424, http://dx.doi.org/10.1038/s41575-018-0026-5
2018
Martinello M; Hajarizadeh B; Dore GJ, 2018, 'Observations on the launch of new drugs for hepatitis C', Australian Prescriber, vol. 41, pp. 4 - 5, http://dx.doi.org/10.18773/austprescr.2018.005
2018
Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J, 2018, 'Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia', International Journal of Drug Policy, vol. 61, pp. 23 - 30, http://dx.doi.org/10.1016/j.drugpo.2018.08.011
2018
Martinello M; Grebely J; Petoumenos K; Gane E; Hellard M; Shaw D; Sasadeusz J; Applegate TL; Dore GJ; Matthews GV, 2017, 'HCV reinfection incidence among individuals treated for recent infection', Journal of Viral Hepatitis, vol. 24, pp. 359 - 370, http://dx.doi.org/10.1111/jvh.12666
2017
Martinello M; Grebely J; Matthews GV, 2017, 'Direct-acting antivirals for acute HCV: how short can we go?', The Lancet Gastroenterology and Hepatology, vol. 2, pp. 316 - 318, http://dx.doi.org/10.1016/S2468-1253(17)30043-2
2017
Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV, 2017, 'HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs', Current HIV/AIDS Reports, vol. 14, pp. 110 - 121, http://dx.doi.org/10.1007/s11904-017-0358-8
2017
Martinello M; Dore GJ; Skurowski J; Bopage RI; Finlayson R; Baker D; Bloch M; Matthews GV, 2016, 'Antiretroviral use in the CEASE cohort study and implications for direct-acting antiviral therapy in human immunodeficiency virus/hepatitis C virus coinfection', Open Forum Infectious Diseases, vol. 3, http://dx.doi.org/10.1093/ofid/ofw105
2016
Martinello M; Gane E; Hellard M; Sasadeusz J; Shaw D; Petoumenos K; Applegate T; Grebely J; Maire L; Marks P; Dore GJ; Matthews GV, 2016, 'Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study', Hepatology, vol. 64, pp. 1911 - 1921, http://dx.doi.org/10.1002/hep.28844
2016
Phillips CJ; Wells NA; Martinello M; Smith S; Woodman RJ; Gordon DL, 2016, 'Evaluating vancomycin susceptibility in Staphylococcus aureus Reply', INFECTION AND DRUG RESISTANCE, vol. 9, pp. 241 - 241
2016
Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2016, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies', Antiviral therapy, vol. 21, pp. 465, http://dx.doi.org/10.3851/IMP3073
2016
Hajarizadeh B; Grebely J; Martinello M; Matthews GV; Lloyd AR; Dore GJ, 2016, 'Hepatitis C treatment as prevention: evidence, feasibility, and challenges', The Lancet Gastroenterology and Hepatology, vol. 1, pp. 317 - 327, http://dx.doi.org/10.1016/S2468-1253(16)30075-9
2016
Martinello M; Schteinman A; Alavi M; Williams K; Dore GJ; Day R; Matthews GV, 2016, 'The impact of ribavirin plasma concentration on the efficacy of the interferon-sparing regimen, sofosbuvir and ribavirin', ANTIVIRAL THERAPY, vol. 21, pp. 127 - 132, http://dx.doi.org/10.3851/IMP2984
2016
Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2016, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies', ANTIVIRAL THERAPY, vol. 21, pp. 425 - 434, http://dx.doi.org/10.3851/IMP3035
2016
Martinello M; Amin J; Matthews GV; Dore GJ, 2016, 'Prevalence and disease burden of HCV coinfection in HIV cohorts in the Asia pacific region: A systematic review and meta-analysis', AIDS Reviews, vol. 18, pp. 69 - 80
2016
Martinello M; Dore GJ, 2016, 'Editorial commentary: Interferon-free Hepatitis C treatment efficacy from clinical trials will translate to "Real World" outcomes', Clinical Infectious Diseases, vol. 62, pp. 927 - 928, http://dx.doi.org/10.1093/cid/civ1227
2016
Phillips CJ; Wells NA; Martinello M; Smith S; Woodman RJ; Gordon DL, 2016, 'Optimizing the detection of methicillin-resistant staphylococcus aureus with elevated vancomycin minimum inhibitory concentrations within the susceptible range', Infection and Drug Resistance, vol. 9, pp. 87 - 92, http://dx.doi.org/10.2147/IDR.S107961
2016
Phillips CJ; Wells NA; Martinello M; Smith S; Woodman RJ; Gordon DL, 2016, 'Authors’ reply', Infection and Drug Resistance, vol. 9, pp. 241
2016
Martinello M; Matthews GV, 2015, 'Enhancing the detection and management of acute hepatitis C virus infection', International Journal of Drug Policy, vol. 26, pp. 899 - 910, http://dx.doi.org/10.1016/j.drugpo.2015.07.003
2015
Martinello M; Chow DH; Danta M; Matthews GV; Dore GJ, 2014, 'Regression of advanced fibrosis following virological response to anti-HCV therapy', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 29, pp. 85 - 85, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000343863000166&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2014
Martinello M; Chow DH; Danta M; Matthews GV; Dore GJ, 2014, 'Safety and efficacy of telaprevir and boceprevir in the "real world": an Australian experience', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 29, pp. 85 - 86, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000343863000167&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2014
Ingram PR; Murray RJ; Cheng AC; Blyth CC; Walls T; Fisher DA; Davis JS; Abbott I; Kanapathipillai R; Madigan V; McLellan D; Briggs S; King C; Hurley J; Lim LL; Kennedy K; Wilson H; Evans T; Maze M; Pithie A; Chong L; Leung G; McCann S; Lee LY; Wolfgang J; Day T; Silva GD; Martinello M; Gliddon T; Wilson M; Athan E; Pollard J; Harris P; Pachchigar R; Wehrhahn M; Moriarty P; Holland D; Langlands A; McBride S; Sherif M; Lim K; Choong K; Henderson A; Sowden D; Everts R; Manon M; Sud A; Read K; Yap R; Bursle E; Gluer R; Siebert D; Cross G; Francis J; Booth C; Dalton S; Ooi EL; Chih D; Dyer J; Clarke J; Grimwood K; Gwee A; Commons R; Majumdar S; Warren S; Manners D; Raby E; Radhakrishnan D; Keighley C; Dotel R; Paterson D; Best E; Aung AK; Paterson T; Hassell M; Newcombe J; Llorin R; Lye D; Giola M; Yew HS; Taylor J; Iredell J; Pollett S; Garg L; Jennings Z; Kapur A; Miyakis S; Parshuramkar D; Thu KM; Rasiah K; Bak N; Chen S; Cooley L; Gordon D; Howden B; McBryde E; Murdoch D; Peleg A; Ralph A; Robinson O, 2014, 'What do infectious diseases physicians do? A 2-week snapshot of inpatient consultative activities across Australia, New Zealand and Singapore', Clinical Microbiology and Infection, vol. 20, pp. O737 - O744, http://dx.doi.org/10.1111/1469-0691.12581
2014
Martinello M; Nelson A; Bignold L; Shaw D, 2012, '“We are what we eat!” Invasive intestinal mucormycosis: A case report and review of the literature', Medical Mycology Case Reports, vol. 1, pp. 52 - 55, http://dx.doi.org/10.1016/j.mmcr.2012.07.003
2012
Lavender CJ; Globan M; Johnson PDR; Charles PGP; Jenkin GA; Ghosh N; Clark BM; Martinello M; Fyfe JAM, 2012, 'Buruli ulcer disease in travelers and differentiation of Mycobacterium ulcerans strains from northern Australia', Journal of Clinical Microbiology, vol. 50, pp. 3717 - 3721, http://dx.doi.org/10.1128/JCM.01324-12
2012
Conference Abstracts
add
Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Reid H; Janjua N; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J, 2019, 'HEPATITIS C VIRUS REINFECTION FOLLOWING ANTIVIRAL TREATMENT AMONG PEOPLE WHO USE OR INJECT DRUGS: A SYSTEMATIC REVIEW AND META-ANALYSIS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S50 - S51, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100127&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2019
Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Reid H; Law M; Janjua N; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore G; Grebely J, 2019, 'Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vienna, AUSTRIA, Vol. 70, pp. E733 - E733, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, AUSTRIA, 10 April 2019 - 14 April 2019, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463481703223&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2019
Hooshyar SH; Martinello M; Yee J; Bartlett S; Read P; Baker D; Post J; Finlayson R; Bloch M; Doyle J; Shaw D; Hellard M; Petoumenos K; Marks P; Applegate T; Dore G; Matthew G, 2019, 'Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vienna, AUSTRIA, Vol. 70, pp. E734 - E734, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, AUSTRIA, 10 April 2019 - 14 April 2019, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463481703225&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2019
Martinello M; Cerrone M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Schoolmeesters A; Grebely J; Nelson M; Matthews GV, 2018, 'TARGET3D: high efficacy of 8 weeks paritaprevir/ritonavir/ombitasvir and dasabuvir among people with recent genotype 1 HCV infection', in HIV MEDICINE, WILEY, Vol. 19, pp. S151 - S152, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000430174700440&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2018
Martinello M; Bartlett S; Dore G; Bopage R; Finlayson R; Baker D; Bloch M; Doyle J; Shaw D; Hajkowicz K; Read P; Filep E; Lin L; Yee J; Applegate T; Hellard M; Matthews G, 2018, 'Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia', in Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia, Paris, France, presented at THE INTERNATIONAL LIVER CONGRESS 2018, Paris, France, 11 April 2018 - 15 April 2018
2018
Martinello M; Bhagani S; Gane EJ; Orkin C; Cooke G; Kulasegaram R; Shaw D; Hellard M; Tu E; Filep E; Petoumenos K; Marks P; Grebely J; Dore GJ; Nelson M; Matthews G, 2017, 'Shortened therapy of 8 weeks duration with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with acute and recent genotype 1 HCV infection: The TARGET3D Study', in HEPATOLOGY, WILEY, Washington, DC, Vol. 66, pp. 574A - 575A, presented at 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Washington, DC, 20 October 2017 - 24 October 2017, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000412089801215&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2017
Martinello M; Dore GJ; Bopage RI; Finlayson R; Baker D; Bloch M; Wilcox A; Filep E; Hellard M; Matthews GV, 2017, 'DAA treatment scale-up in HIV/HCV co-infection: characterisinga population at risk for reinfection', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Amsterdam, NETHERLANDS, Vol. 66, pp. S495 - S496, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31388-0
2017
Martinello M; Petoumenos K; Grebely J; Gane E; Hellard M; Shaw D; Sasdeusz J; Applegate T; Lamoury F; Yeung B; Maire L; Dore G; Matthews G, 2016, 'INCIDENCE OF HCV REINFECTION AMONG TREATED INDIVIDUALS WITH RECENTLY ACQUIRED INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Barcelona, SPAIN, Vol. 64, pp. S620 - S621, presented at EASL International Liver Congress, Barcelona, SPAIN, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01152-1
2016
Book Chapters
add
Martinello M; Hajarizadeh B; Grebely J; Matthews G; Dore G, 2019, 'Cure and Control: What Will It Take to Eliminate HCV?', in Sofia M (ed.), HCV: The Journey from Discovery to a Cure: Volume II, Springer International Publishing, pp. 447 - 490, http://dx.doi.org/10.1007/7355_2018_56
2019
Mills J; Crowe SM; Martinello MK, 2017, 'Investigational antiviral drugs', in Kucers' The Use of Antibiotics A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition - Three Volume Set, CRC Press
2017
Martinello MK; Grebely J; Dore G, 2017, 'Protease, polymerase and assembly inhibitors for the treatment of hepatitis C virus infection', in Kucers' The Use of Antibiotics A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition - Three Volume Set, CRC Press, pp. 4409 - 4431, http://dx.doi.org/10.1201/9781315152110
2017
Matthews G; Martinello MK; van Beek I; Burns M, 2014, 'Exposure and acute viral hepatitis', in HIV, Viral Hepatitis and STIs: A Guide for Primary Care
2014
Conference Presentations
add
Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2017, 'The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments', Vol. 66, pp. S291 - S292, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30899-1
2017
Hajarizadeh B; Grebely J; Matthews G; Martinello M; Dore G, 2016, 'Treatment uptake for chronic hepatitis C in Australia following universal access to interferon-free treatments', Vol. 64, pp. 948A - 948A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, MA, 11 November 2016 - 15 November 2016, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493804277&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2016
Conference Papers
add
Martinello M; Schteinman A; Alavi M; Williams K; Dore GJ; Day R; Matthews GV, 2016, 'The impact of ribavirin plasma concentration on the eficacy of the interferon-sparing regimen, sofosbuvir and ribavirin', in Antiviral Therapy, pp. 127 - 132, http://dx.doi.org/10.3851/IMP2984
2016
Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2016, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: The ATAHC II and DARE-C i studies', in Antiviral Therapy, pp. 425 - 434, http://dx.doi.org/10.3851/IMP3035
2016
Lamoury F; Hajarizadeh B; Martinello M; Soker A; Martinez D; Cunningham P; Cloherty GA; Marks P; Matthews G; Amin J; Grebely J; Dore G; Applegate TL, 2016, 'Hepatitis C virus core antigen: A simplified treatment monitoring tool among those with recent Hepatitis C virus infection, including for post-treatment relapse', in HEPATOLOGY, WILEY, Boston, MA, pp. 415A - 415A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, MA, 11 November 2016 - 15 November 2016, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493802113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2016